Asian Pacific Journal of Cancer Prevention

Asian Pacific Journal of Cancer Prevention (아시아태평양암예방학회)
권호 표지
DOI QR코드

DOI QR Code

Continuous-infusion Ifosfamide and Doxorubicin Combination as Second-Line Chemotherapy for Recurrent or Refractory Osteosarcoma Patients in China: a Retrospective Study

  • Huang, Yu-Jing (Department of Oncology, Affiliated Sixth People's Hospital, Shanghai Jiaotong University) ;
  • He, Ai-Na (Department of Oncology, Affiliated Sixth People's Hospital, Shanghai Jiaotong University) ;
  • Sun, Yuan-Jue (Department of Oncology, Affiliated Sixth People's Hospital, Shanghai Jiaotong University) ;
  • Shen, Zan (Department of Oncology, Affiliated Sixth People's Hospital, Shanghai Jiaotong University) ;
  • Min, Da-Liu (Department of Oncology, Affiliated Sixth People's Hospital, Shanghai Jiaotong University) ;
  • Yao, Yang (Department of Oncology, Affiliated Sixth People's Hospital, Shanghai Jiaotong University)
  • Published : 2015.04.03
Download PDF
⟨ Previous Next ⟩

Abstract

Objective: The aim of this retrospective study was to evaluate the feasibility and efficacy of response to continuous-infusion ifosfamide and doxorubicin combination as second-line chemotherapy for patients with recurrent or refractory osteosarcoma. Materials and Methods: Eighteen recurrent or refractory osteosarcoma patients who were treated with continuous-infusion ifosfamide and doxorubicin combination between May 1999 and April 2011 were included in the analysis. Ifosfamide at $12g/m^2$ was administered by intravenous continuous infusion over 3 days, and doxorubicin $60mg/m^2$ was administered as an intravenous bolus injection on day 1. The combination therapy was repeated every 3 weeks. Treatment was continued until evidence of disease progression or unacceptable toxicity. Results: The patients (ages 7-53 years) received a total of 42 cycles of chemotherapy (median: 2 courses; range: 2-5 courses). The overall response rate was 0% and the disease control rate was 22.3%, with four patients having stable disease. The median time to progression and overall survival time were 2 months (range: 2-5 months) and 9 months (range: 3-29 months), respectively. Major severe toxicities were leucopenia 7 (38.9%), nausea and vomiting 3 (16.7%) and alopecia 9 (50%). There were no treatment-related deaths. Conclusions: In our experience, continuous-infusion ifosfamide and doxorubicin combination therapy at this dosage and schedule was found to be well tolerated and moderate effective, which could be considered as salvage therapy for patients with recurrent or refractory osteosarcoma. Further assessment is necessary to confirm the safety and efficacy of this treatment.

Keywords

References

  1. Bacci G, Ferrari S, Lari S, et al (2002). Osteosarcoma of the limb. Amputation or limb salvage in patients treated by neoadjuvant chemotherapy. J Bone Joint Surg Br, 84, 88-92. https://doi.org/10.1302/0301-620X.84B1.12211
  2. Bagatell R, Norris R, Ingle AM, et al (2014). Phase 1 trial of temsirolimus in combination with irinotecan and temozolomide in children, adolescents and young adults with relapsed or refractory solid tumors: a Children's Oncology Group Study. Pediatr Blood Cancer, 61, 833-9. https://doi.org/10.1002/pbc.24874
  3. Bielack SS, Kempf-Bielack B, Delling G, et al (2002). Prognostic factors in high-grade osteosarcoma of the extremities or trunk: an analysis of 1, 702 patients treated on neoadjuvant cooperative osteosarcoma study group protocols. J Clin Oncol, 20, 776-90. https://doi.org/10.1200/JCO.20.3.776
  4. Bond M, Bernstein ML, Pappo A, et al (2008). A phase II study of imatinib mesylate in children with refractory or relapsed solid tumors: a Children's Oncology Group study. Pediatr Blood Cancer, 50, 254-8. https://doi.org/10.1002/pbc.21132
  5. Brennan RC, Furman W, Mao S, et al (2014). Phase I dose escalation and pharmacokinetic study of oral gefitinib and irinotecan in children with refractory solid tumors. Cancer Chemother Pharmacol, 74, 1191-8. https://doi.org/10.1007/s00280-014-2593-7
  6. Cartei G, Clocchiatti L, Sacco C, et al (2003). Dose finding of ifosfamide administered with a chronic two-week continuous infusion. Oncology, 65, 31-6. https://doi.org/10.1159/000073355
  7. Choeyprasert W, Pakakasama S, Sirachainan N, et al (2014). Comparative outcome of Thai pediatric osteosarcoma treated with two protocols: the role of high-dose methotrexate (HDMTX) in a single institute experience. Asian Pac J Cancer Prev, 15, 9823-9. https://doi.org/10.7314/APJCP.2014.15.22.9823
  8. Chuk MK, Aikin A, Whitcomb T, et al (2012). A phase I trial and pharmacokinetic study of a 24-hour infusion of trabectedin (Yondelis (R), ET-743) in children and adolescents with relapsed or refractory solid tumors. Pediatr Blood Cancer, 59, 865-9. https://doi.org/10.1002/pbc.24201
  9. Crews KR, Stewart CF, Liu T, et al (2004). Effect of fractionated ifosfamide on the pharmacokinetics of irinotecan in pediatric patients with osteosarcoma. J Pediatr Hematol Oncol, 26, 764-7. https://doi.org/10.1097/00043426-200411000-00016
  10. De Pas T, Rosati G, Spitaleri G, et al (2011). Optimizing clinical care in patients with advanced soft tissue sarcoma: a phase II study of a new schedule of high-dose continuous infusion ifosfamide and doxorubicin combination. Chemotherapy, 57, 217-24. https://doi.org/10.1159/000326466
  11. Ferrari S, Briccoli A, Mercuri M, et al (2003). Postrelapse survival in osteosarcoma of the extremities: prognostic factors for long-term survival. J Clin Oncol, 21, 710-5. https://doi.org/10.1200/JCO.2003.03.141
  12. Harris MB, Cantor AB, Goorin AM, et al (1995). Treatment of osteosarcoma with ifosfamide: comparison of response in pediatric patients with recurrent disease versus patients previously untreated: a Pediatric Oncology Group study. Med Pediatr Oncol, 24, 87-92. https://doi.org/10.1002/mpo.2950240205
  13. Hawkins DSand Arndt CA (2003). Pattern of disease recurrence and prognostic factors in patients with osteosarcoma treated with contemporary chemotherapy. Cancer, 98, 2447-56. https://doi.org/10.1002/cncr.11799
  14. Kobys VL, Konovalenko VF, Repinsmall a CNV, et al (2013). Treatment of large osteosarcoma in children: new approach. Exp Oncol, 35, 105-8.
  15. Kudawara I, Aoki Y, Ueda T, et al (2013). Neoadjuvant and adjuvant chemotherapy with high-dose ifosfamide, doxorubicin, cisplatin and high-dose methotrexate in non-metastatic osteosarcoma of the extremities: a phase II trial in Japan. J Chemother, 25, 41-8. https://doi.org/10.1179/1973947812Y.0000000055
  16. Li YY, Jiang XM, Dong YG, Xu G, Ma YB (2014). Ifosfamide-containing regimens for treating patients with osteosarcomas. Asian Pac J Cancer Prev, 15, 9763-6. https://doi.org/10.7314/APJCP.2014.15.22.9763
  17. Meyers PA, Schwartz CL, Krailo M, et al (2005). Osteosarcoma: a randomized, prospective trial of the addition of ifosfamide and/or muramyl tripeptide to cisplatin, doxorubicin, and high-dose methotrexate. J Clin Oncol, 23, 2004-11. https://doi.org/10.1200/JCO.2005.06.031
  18. Palumbo R, Palmeri S, Antimi M, et al (1997). Phase II study of continuous-infusion high-dose ifosfamide in advanced and/or metastatic pretreated soft tissue sarcomas. Ann Oncol, 8, 1159-62. https://doi.org/10.1023/A:1008279426654
  19. Qi WX, He AN, Tang LN, et al (2012). Efficacy and safety of gemcitabine-docetaxel combination therapy for recurrent or refractory high-grade osteosarcoma in China: a retrospective study of 18 patients. Jpn J Clin Oncol, 42, 427-31. https://doi.org/10.1093/jjco/hys030
  20. Qi WX, He AN, Tang LN, et al (2012). Evaluation of pirarubicin-cisplatin chemotherapy in the treatment for refractory and recurrent high-grade osteosarcoma: experience of a single institute. Med Oncol, 29, 2229-33. https://doi.org/10.1007/s12032-011-0021-y
  21. Saeter G, Hoie J, Stenwig AE, et al (1995). Systemic relapse of patients with osteogenic sarcoma. Prognostic factors for long term survival. Cancer, 75, 1084-93. https://doi.org/10.1002/1097-0142(19950301)75:5<1084::AID-CNCR2820750506>3.0.CO;2-F
  22. Seibel NL, Krailo M, Chen Z, et al (2007). Upfront window trial of topotecan in previously untreated children and adolescents with poor prognosis metastatic osteosarcoma: children's Cancer Group (CCG) 7943. Cancer, 109, 1646-53. https://doi.org/10.1002/cncr.22553
  23. Singer JM, Hartley JM, Brennan C, et al (1998). The pharmacokinetics and metabolism of ifosfamide during bolus and infusional administration: a randomized cross-over study. Br J Cancer, 77, 978-84. https://doi.org/10.1038/bjc.1998.161
  24. Sluga M, Windhager R, Lang S, et al (1999). Local and systemic control after ablative and limb sparing surgery in patients with osteosarcoma. Clin Orthop Relat Res, 120-7.
  25. Ta HT, Dass CR, Choong PF, et al (2009). Osteosarcoma treatment: state of the art. Cancer Metastasis Rev, 28, 247-63. https://doi.org/10.1007/s10555-009-9186-7
  26. Therasse P, Arbuck SG, Eisenhauer EA, et al (2000). New guidelines to evaluate the response to treatment in solid tumors. european organization for research and treatment of cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst, 92, 205-16. https://doi.org/10.1093/jnci/92.3.205
  27. Wilkins RM, Cullen JW, Odom L, et al (2003). Superior survival in treatment of primary nonmetastatic pediatric osteosarcoma of the extremity. Ann Surg Oncol, 10, 498-507. https://doi.org/10.1245/ASO.2003.03.061

Cited by

  1. Association of Metastasis with Clinicopathological Data in Mexican Patients with Osteosarcoma, Giant Cell Tumor of Bone and Chondrosarcoma vol.16, pp.17, 2015, https://doi.org/10.7314/APJCP.2015.16.17.7689